TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to a December 18, 2015 agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.), it has agreed to co-develop and market a portfolio of niche products that will be sold on the TruPharma label. The current product portfolio consists of multiple products, some of which are pending with FDA and others are to be developed in the next eighteen months. The agreement contemplates that additional products will be added for future development. TruPharma expects the first of the pending ANDA products to receive FDA approval and to be launched in 2016.